MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, K. J.
Right arrow Articles by Liao, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, K. J.
Right arrow Articles by Liao, J. K.
Molecular Interventions 2:219-228 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics

Review

Non-nuclear Actions of Estrogen: New Targets for Prevention and Treatment of Cardiovascular Disease

Karen J. Ho, MD and James K. Liao, MD

The Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Cambridge, MA 02139, USA



   SUMMARY
TOP
 Summary
INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
Gender-based differences in the incidence of hypertensive and coronary artery disease, the development of atherosclerosis, and myocardial remodeling after infarction are attributable to the indirect effect of estrogen on risk factor profiles, such as cholesterol levels, glucose metabolism, and insulin levels. More recent evidence, however, suggests that activated estrogen receptor (ER) mediates signaling cascades that culminate in direct protective effects such as vasodilation, inhibition of response to vessel injury, limiting myocardial injury after infarction, and attenuating cardiac hypertrophy. Although the ER is usually thought of as a ligand-dependent transcription factor, it can also rapidly mobilize signals at the plasma membrane and in the cytoplasm. Thus, a greater understanding of ER function and regulation may lead to the development of highly specific therapeutics that mediate the prevention and treatment of cardiovascular diseases.


   INTRODUCTION
TOP
 Summary
 INTRODUCTION
ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
Gender-based differences in the incidence of hypertensive and coronary artery disease, the development of atherosclerosis, and myocardial remodeling after infarction are attributable to the indirect effect of estrogen on risk factor profiles, such as cholesterol levels, glucose metabolism, and insulin levels (1–3), as well as its direct effects on the myocardium, vascular smooth muscle and endothelium. Although estrogen receptor (ER) is typically thought of as a ligand-dependent transcription factor, it also modulates the activity of intracellular second messengers and membrane-associated signaling complexes. In the heart and vasculature, these non-nuclear signaling pathways mediate rapid vasodilation (4), inhibition of response to vessel injury (5–10), reduction in myocardial injury after infarction (11, 12), and attenuation of cardiac hypertrophy (13, 14).


   ESTROGEN RECEPTOR STRUCTURE AND FUNCTION
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
Both subtypes of ER, ER{alpha} and ERß, are members of the nuclear receptor superfamily (15, 16). They are synthesized from separate genes and are structurally and functionally distinct. Classically, ER regulates gene expression in target tissues in a ligand-dependent manner: the binding of estradiol (E2) releases ER from an inhibitory complex and allows for receptor homodimerization and translocation into the nucleus (1, 2, 17). The receptor then binds a palindromic estrogen response element (ERE) located in the promoter region of target genes. The concerted actions of the ligand-independent activation function domain (AF-1) in the N terminus (Figure 1Go) and the ligand-dependent AF-2 region in the hormone-binding domain lead to the recruitment of tissue-, cell-, and promoter-specific co-regulator complexes to the ERE, resulting in transactivation or transrepression (18, 19).



View larger version (16K):
[in this window]
[in a new window]
  		Figure 1. Functional regions of the human estrogen receptor {alpha} (ER{alpha}). These domains include a ligand-independent transactivation function domain (AF-1), DNA-binding domain, hormone-binding domain and ligand-dependent transactivation function domain (AF-2). Putative regions of interaction with other proteins and sites of phosphorylation by various kinases are also shown.

 
Gene deletion or mutation studies have underlined the importance of ER in cardiovascular physiology (20). Early studies of ovariectomized mice demonstrated that E2 inhibits the proliferation of intimal and medial vascular smooth muscle (5), suggesting a direct protective effect of estrogen on endothelium and vascular smooth muscle cells (VSMCs). In ER{alpha} and ERß double-knockout mice, however, E2 inhibits VSMC proliferation but not medial thickening, suggesting that a leakily expressed splice-variant of ER{alpha} could mediate partial protection (21, 22). The more recent production of complete ER{alpha}-null mice (23), which exhibit increased medial area, VSMC proliferation, and deposition of proteoglycans in response to vascular injury, has confirmed the role of ER{alpha} in vascular protection (24). The effects also extend to the myocardium. For example, ER{alpha}-deficient hearts subjected to whole-organ ischemia and reperfusion (25) exhibit greater ischemia and higher incidence of arrhythmias than that observed in wild-type hearts. The process may involve nitric oxide (NO), which ameliorates coronary dysfunction and reduces tissue edema by decreasing microvascular permeability, because ER{alpha}-deficient hearts also demonstrate decreased NO release.

In 1975, Pietras and Szego first described membrane binding sites for estrogen and described a non-genomic mechanism for calcium influx in endometrial cells (26). More recent studies have added to our current understanding of the highly tissue-specific, non-nuclear ER{alpha} signaling network. Though there is also evidence that ERß has an important function in the vasculature (27, 28), we focus on ER{alpha} because of the greater number of observations that have been made. Defining the cascades through which ER{alpha} elicits its pleiotropic cellular effects and understanding the dysregulation of the network in disease states promises to uncover novel targets for pharmacological intervention.


   NON-NUCLEAR ACTIVITY OF ESTROGEN
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
Estrogenic transcription-dependent effects, such as those that contribute prominently in organogenesis and function of the reproductive system, become evident hours after stimulation. Non-nuclear (alternatively referred to as "non-transcriptional" or "non-genomic") estrogenic action peaks minutes after stimulation in multiple cell types. Other characteristics include immunity to inhibitors of DNA transcription or protein synthesis (actinomycin D or cycloheximide) and recruitment of membrane or cytosol-localized signaling components. These include the second messengers calcium and nitric oxide (NO), receptor tyrosine kinases including the epidermal growth factor receptor (EGFR) and insulin-like growth factor-1 (IGF-1) receptor (IGF1R), G protein coupled receptors (GPCRs), and protein kinases including phosphatidylinositol-3' kinase (PI3K), the serine-threonine kinase Akt, mitogen-activated protein kinase (MAPK) family members, the non-receptor tyrosine kinase Src, and protein kinases A and C (PKA and PKC, respectively) (Figure 2Go) (for reviews see 17, 29, 30).



View larger version (71K):
[in this window]
[in a new window]
  		Figure 2. Selected nuclear and non-nuclear activities of ER{alpha}. Details are described in the text. Abbreviations: endothelial nitric oxide synthase (eNOS), nitric oxide (NO), heat shock protein 90 (HSP90), phosphatidylinositol-3' kinase (PI3K), son of sevenless (Sos), growth factor receptor binding protein 2 (Grb2), G protein coupled receptor (GPCR), protein kinase A (PKA), protein kinase C (PKC), extracellular-regulated kinases 1 and 2 (ERK1/2), Jun N-terminal kinase (JNK), 38-kDa isoform of MAPK (p38), estrogen response element (ERE).

 

   SIGNALING CASCADES ACTIVATED BY ESTROGEN
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
The PI3K-Akt signaling cascade is one downstream target of non-nuclear estrogenic signaling (31–33). In the vasculature, short-term exposure to E2 leads to NO-dependent vasodilation (34). The secretion of NO by healthy vessels relaxes smooth muscle cells and inhibits platelet activation in a cyclic guanosine 3', 5'-monophosphate (cGMP)-dependent mechanism. In cultured endothelial cells, estrogen enhances NO release within minutes without altering expression of endothelial nitric oxide synthase (eNOS) (33, 35). E2 activates eNOS activity in a biphasic manner through MAPK and PI3K-Akt pathways, leading to enhanced NO release (32). Myocardial protection by high-dose corticosteroids during ischemia-reperfusion injury also appears to be mediated by PI3K-Akt (36). In both cases, ER{alpha} and glucocorticoid receptors activate PI3K by associating with the p85{alpha} regulatory subunit in a ligand-dependent manner (32). Furthermore, the 90-kDa heat shock protein (HSP90) interacts with both eNOS and Akt and modulates eNOS activity by acting as a scaffold to regulate Akt-dependent phosphorylation of eNOS (37).

MAPK family members are common targets of non-nuclear estrogenic signaling. Induction of eNOS and inducible NOS (iNOS) expression in cardiac myocytes is blocked by the MAPK inhibitor PD98059 (38). This may be clinically relevant since NO inhibits the activation of caspases and prevents the development of congestive heart failure (39). Estrogen also activates extracellular-regulated kinases 1 and 2 (ERK1/2) in cardiomyocytes (38), colon cancer (40), breast cancer (41), and bone (42, 43), and inhibits ERK1/2 in VSMCs (44) and lung myofibroblasts (45). In the heart, ER{alpha} also selectively activates the 38-kDa isoform of MAPK (p38) to modulate the development of pressure-overload hypertrophy (13, 14, 46, 47), which is consistent with recruitment of p38 in other models of cardiac hypertrophy (48, 49). In endothelial cells, estrogen prevents disruption of the actin cytoskeleton during ischemia, prevents cell death, and enhances injury-dependent angiogenesis by rapidly and selectively activating the anti-apoptotic ß isoform of p38 (p38ß) and inhibiting pro-apoptotic p38{alpha}, leading to the increased expression of MAPK-activated protein kinase-2 (MAPKAP-2) kinase and phosphorylation of HSP27 (50). Downstream effects include preservation of stress fiber formation and membrane integrity, prevention of hypoxia-induced apoptosis, and induction of both endothelial cell (EC) migration and the formation of primitive capillary tubes (50).

It is possible that ER{alpha} might direct the activation of more receptor-proximal signaling complexes located at the plasma membrane. When overexpressed in cells, ligand-bound ER{alpha} induces the rapid phosphorylation of IGF1R and the activation of ERK1/2. Because these receptors co-immunoprecipitate in a ligand-dependent manner, a direct physical interaction between ER{alpha} and IGF1R could conceivably mediate the activation of ERK1/2 (51). In breast cancer cell lines, ligand-bound ER{alpha} promotes the rapid phosphorylation of the proteins Src and Shc, resulting in the formation of a Shc-Grb2- (growth factor receptor binding protein 2)-Sos (son of sevenless) complex (52), leading to downstream activation of Ras, Raf, and MAPK. Similarly, in both breast cancer and prostate cancer cells, E2 treatment induces the association of ER{alpha} phospho-Tyr537 with the Src SH2 (Src homology 2) domain, leading to activation of the Src-Ras-ERK pathway and cell cycle progression (53, 54). Additionally, in breast cancer cells, Src modulates PI3K-Akt signaling through a reversible cross-talk mechanism whereby the ligand-bound ER forms a ternary complex composed of ER{alpha}, PI3K, and Src (55). Cross-talk between PI3K and Src has also been observed in osteoclasts and bone marrow cells (56, 57).

Non-nuclear signaling can also amplify the nuclear, transcriptional activity of ER{alpha}. For example, in lactotroph cells, E2 rapidly activates ERK1/2, leading to increased transcription of the prolactin (PRL) gene, thus creating an additive effect on PRL expression by complementing the direct ERE-dependent transcriptional activation of PRL by ER{alpha} (58). Non-nuclear ER{alpha} activity can also elicit ERE-independent transcriptional activation. In cardiac myocytes, E2 rapidly increases ERK1/2-dependent expression of the early growth response-1 gene (egr-1) by inducing the recruitment of serum response factor (SRF) to serum response elements (SREs) in the egr-1 promoter (59).

Growth factors such as EGF and IGF-1 can stimulate the nuclear activity of ER{alpha} through a non-nuclear, E2-independent mechanism. Through the cross-talk of molecular networks, mitogenic extracellular signals are translated into cell cycle progression or, in cancer cells, into hormone-independent proliferation (60). EGF- and IGF-1–mediated stimulation of MAP kinases result in the direct phosphorylation of ER{alpha} on Ser118 (42, 61, 62), which enhances the binding of p68 RNA helicase (63), and promotes AF-1-dependent transcriptional activity in uterine (64, 65) and ovarian adenocarcinoma cells (66). Nuclear coregulator proteins can also be phosphorylated by ERK1/2 leading to increased transcriptional activity (67). Lastly, Src may enhance AF-1 function of ER{alpha} through either a Src, Raf-1, mitogen-activated ERK kinase (MEK) and ERK pathway that leads to phosphorylation of Ser118, or a pathway that includes Src, MEK kinase (MEKK), Jun N-terminal kinase (JNK) kinase (JNKK), and JNK, and that regulates AF-1-associated coactivators (68).


   MECHANISMS FOR ER{alpha} ACTIVITY AT THE PLASMA MEMBRANE
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
Membrane binding sites for E2 were first implicated in 1977 (26), and additional indirect evidence for a membrane-associated ER{alpha} comes from immunohistochemistry (69, 70), overexpressed nuclear receptors (71), or studies with membrane-impermeable ligands (72–74). The trafficking of ER{alpha} to different cellular compartments may be regulated by the nature of the stimulation; for example, in VSMCs transfected with ER{alpha}, MAPK activation mediates the nuclear translocation of ER{alpha} from the membrane fraction by both E2-dependent and -independent mechanisms (75). However, because ER{alpha} has no intrinsic kinase or phosphatase activity, does not have hydrophobic stretches that could represent transmembrane domains, and lacks myristoylation and palmitoylation sequences that could anchor it to the membrane, membrane localization of the receptor seems unlikely. Alternatively, the receptor may associate with membrane caveolae: in fractionated plasma membranes from endothelial cells (ECs), ER{alpha} is localized to caveolae, and E2 stimulates eNOS in isolated caveolae in an ER{alpha}- and calcium-dependent manner (76–78). There is evidence that within the caveolae of ECs, HSP90, eNOS, and cav-1 (caveolin-1, the coat protein of caveolae) exist in a heterotrimeric complex that modulates eNOS activity depending on intracellular calcium levels (79, 80).

Non-nuclear ER{alpha} signaling also involves membrane-associated heterotrimeric G proteins. In Chinese hamster ovary (CHO) cells transfected with ER{alpha} cDNA, treatment of membrane fractions with estrogen activated G{alpha}q and G{alpha}s and rapidly stimulated inositol phosphate production and adenylyl cyclase activity, respectively (71). G protein activation also occurs in ECs, where E2 activation of eNOS can be inhibited with the ER antagonist ICI 182,780, RGS-4 (a regulator of G protein signaling specific for G{alpha}i and G{alpha}q), or pertussis toxin (specific for G{alpha}i) (81).


   POSSIBLE NEW ESTROGEN RECEPTORS
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 
Non-nuclear signaling may involve a receptor altogether distinct from the classical ER{alpha}. In macrophage cells, E2 and E2-BSA induce a rise in intracellular calcium that is inhibitable with pertussis toxin (82, 83). The existence of an E2-GPCR in the hippocampus has also been hypothesized, where E2 stimulation potentiates kainate-induced currents through modulation of PKA activity (84).

The most notable evidence that estrogen’s non-nuclear effects are mediated by a receptor distinct from ER{alpha} or ERß has come from studies in the cerebral cortex, where estrogen rapidly stimulates tyrosine phosphorylation of Src, leading to subsequent Shc–Grb2 complex formation upstream of ERK and B-Raf activation (85, 86). The pathway is not inhibitable by ICI 182,780 in cortical explants from ER{alpha}-deficient mice, suggesting that a new receptor, responsive to E2 but insensitive to ICI 182,780, mediates non-nuclear neuronal differentiation.

The nature of the ER{alpha} that mediates the non-nuclear effects of estrogen clearly requires further definition: the distinction between classical and atypical ER{alpha} might be made using cells cultured from complete ER{alpha} knockout mice, and ER{alpha}-truncated mutants might provide insight into the specific domains that mediate non-nuclear effects.


   NON-NUCLEAR PHARMACOLOGICAL TARGETS
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
SUMMARY
 Acknowledgements
 References
 
Nonetheless, an increasingly detailed understanding of the ER signaling network and its pleiotropic cellular effects have made the receptor an attractive pharmacological target. Selective estrogen receptor modulators (SERMs) are ER ligands which can have varying degrees of agonist or antagonist activities depending on the cell, promoter and coregulator context (87, 88) (Table 1Go).


View this table:
[in this window]
[in a new window]
  		TABLE 1. TISSUE-SPECIFIC EFFECTS OF SELECTED SERMS
 
Tamoxifen, the prototypical SERM, renders indirect cardiovascular protective effects by reducing the amounts of serum total cholesterol and low-density lipoprotein (LDL) (89). Unfortunately, its strong agonist activity in the endometrium leads to endometrial hyperplasia and low-grade cancers. Raloxifene, a non-steroidal compound, is similar to tamoxifen but it is less agonistic in the endometrium (90). Though administered primarily for bone preservation, raloxifene also reduces serum triglycerides and serum fibrinogen levels (91). Like estrogen, raloxifene and its analog LY117018 (92) stimulate eNOS activity in endothelial cells through PI3K- and ERK-dependent pathways, respectively (93), both of which may be involved in coronary artery relaxation (94). Raloxifene also improves endothelium-dependent vasorelaxation in hypertensive rats by enhancing the expression and activity of NOS (95).

EM-800, a non-steroidal compound, has higher affinity for ER{alpha} than any other SERM (96). In addition to demonstrating potent antitumor activity in the uterus and breast, EM-800 may also prevent bone loss and lower serum cholesterol and triglyceride levels (97). Furthermore, in vitro studies in endothelial cells suggest that EM-800, like E2, enhances NO release by sequential activation of MAPKs and PI3K-Akt, implicating a direct vascular protective effect (98).

The tissue specificity of SERMs suggests context-specific regulatory mechanisms that depend on the ligand, the promoter of the target gene, and the combination and exchange of co-regulators (99, 100). Breast cancer and pituitary lactotroph tumors, for example, demonstrate enhanced apoptosis and tumor shrinkage when transfected with adenovirus constructs containing dominant-negative ER{alpha} mutants (101). Because dominant-negative ER{alpha} and antiestrogens both recruit transcriptionally repressive proteins to the ER{alpha} DNA-binding complex (102, 103), the co-regulatory proteins that govern ER{alpha} activity, in addition to the receptor itself, represent promising therapeutic targets.


   SUMMARY
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
Acknowledgements
 References
 
We are just beginning to appreciate the complexity of ER{alpha} signaling. Future research efforts will undoubtedly reveal the intricacies of expression and translocation of endogenous ER{alpha} and possibly the identity of a new receptor that binds E2 and activates non-nuclear signaling. Furthermore, the activity of coregulators and their role in distinguishing the nuclear and non-nuclear activities of ER{alpha} remain to be defined. A full understanding of these highly cell- and promoter-specific mechanisms will allow the development of specific agonists and antagonists that selectively elicit only the beneficial effects of estrogen.


James K. Liao, MD, (left) is the Director of the Vascular Medicine Research Unit at the Brigham and Women’s Hospital, and is a Associate Professor of Medicine at Harvard Medical School. Address comments to JKL. E-mail jliao{at}rics.bwh.harvard.edu. Fax 617-768-8425 Karen J. Ho, MD, (right) is a member of the Vascular Medicine Research Unit, Brigham and Women’s Hospital and Harvard Medical School.


   ACKNOWLEDGEMENTS
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
References
 
J.K. Liao is an Established Investigator of the American Heart Association. K.J. Ho is a Howard Hughes Medical Institute Medical Student Fellow. We thank Dr. A. Senes and S. Gainsbourg for assistance in preparing the manuscript. We apologize to all authors whose work could not be cited due to space limitations.


   References
TOP
 Summary
 INTRODUCTION
 ESTROGEN RECEPTOR STRUCTURE AND...
 NON-NUCLEAR ACTIVITY OF ESTROGEN
 SIGNALING CASCADES ACTIVATED BY...
 MECHANISMS FOR ER{alpha}...
 POSSIBLE NEW ESTROGEN RECEPTORS
 NON-NUCLEAR PHARMACOLOGICAL...
 SUMMARY
 Acknowledgements
 References
 

  1. Mendelsohn, M.E. and Karas, R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340,1801–1811 (1999).[Free Full Text]
  2. Babiker, F.A., De Windt , L.J., van Eickels, M., Grohe, C., Meyer, R., and Doevendans, P.A. Estrogenic hormone action in the heart: Regulatory network and function. Cardiovasc. Res. 53, 709–719 (2002).[Abstract/Free Full Text]
  3. Stevenson, J.C. Cardiovascular effects of oestrogens. J. Steroid. Biochem. Mol. Biol. 74, 387–393 (2000).[CrossRef][Medline]
  4. White, R.E., Darkow, D.J., and Lang, J.L. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ. Res. 77, 936–942 (1995).[Abstract/Free Full Text]
  5. Sullivan, Jr., T.R., Karas, R.H., Aronovitz, M., Faller, G.T., Ziar, J.P., Smith, J.J., O’Donnell, Jr., T.F., and Mendelsohn, M.E. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J. Clin. Invest. 96, 2482–2488 (1995).
  6. Bourassa, P.A., Milos, P.M., Gaynor, B.J., Breslow, J.L., and Aiello, R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 93, 10022–10027 (1996).[Abstract/Free Full Text]
  7. Chen, S.J., Li, H., Durand, J., Oparil, S., and Chen, Y.F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93, 577–584 (1996).[Abstract/Free Full Text]
  8. Akishita, M., Ouchi, Y., Miyoshi, H., Kozaki, K., Inoue, S., Ishikawa, M., Eto, M., Toba, K., and Orimo, H. Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: Effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130:1–10 (1997).[CrossRef][Medline]
  9. Oparil, S., Levine, R.L., Chen, S.J., Durand, J., and Chen, Y.F. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 95, 1301–1307 (1997).[Abstract/Free Full Text]
  10. White, C.R., Shelton, J., Chen, S.J., Darley-Usmar, V., Allen, L., Nabors, C., Sanders, P.W., Chen, Y.F., and Oparil, S. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation 96, 1624–1630 (1997).[Abstract/Free Full Text]
  11. McHugh, N.A., Cook, S.M., Schairer, J.L., Bidgoli, M.M., and Merrill, G.F. Ischemia- and reperfusion-induced ventricular arrhythmias in dogs: Effects of estrogen. Am. J. Physiol. 268, H2569–H2573 (1995).[Abstract/Free Full Text]
  12. Node, K., Kitakaze, M., Kosaka, H., Minamino, T., Funaya, H., and Hori, M. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17ß-estradiol: Role of nitric oxide and calcium-activated potassium channels. Circulation 96, 1953–1963 (1997).[Abstract/Free Full Text]
  13. Farhat, M.Y., Chen, M.F., Bhatti, T., Iqbal, A., Cathapermal, S., and Ramwell, P.W. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br. J. Pharmacol. 110, 719–723 (1993).[Medline]
  14. Douglas, P.S., Katz, S.E., Weinberg, E.O., Chen, M.H., Bishop, S.P., and Lorell, B.H. Hypertrophic remodeling: Gender differences in the early response to left ventricular pressure overload. J. Am. Coll. Cardiol. 32, 1118–1125 (1998).[Abstract/Free Full Text]
  15. Mangelsdorf, D.J., Thummel, C., Beato, M. et al. The nuclear receptor superfamily: The second decade. Cell 83, 835–839 (1995).[CrossRef][Medline]
  16. Beato, M., Herrlich, P., and Schutz, G. Steroid hormone receptors: Many actors in search of a plot. Cell 83, 851–857 (1995).[CrossRef][Medline]
  17. Hall, J.M., Couse, J.F., and Korach, K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276, 36869–36872 (2001).[Free Full Text]
  18. Rosenfeld, M.G., and Glass, C.K. Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem. 276, 36865–36868 (2001).[Free Full Text]
  19. McDonnell, D.P. and Norris, J.D. Connections and regulation of the human estrogen receptor. Science 296, 1642–1644 (2002).[Abstract/Free Full Text]
  20. Couse, J.F. and Korach, K.S. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 20, 358–417 (1999).[Abstract/Free Full Text]
  21. Karas, R.H., Schulten, H., Pare, G., Aronovitz, M.J., Ohlsson, C., Gustafsson, J.A., and Mendelsohn, M.E. Effects of estrogen on the vascular injury response in estrogen receptor {alpha}, ß double knockout mice. Circ. Res. 89, 534–539 (2001).[Abstract/Free Full Text]
  22. Pendaries, C., Darblade, B., Rochaix, P., Krust, A., Chambon, P., Korach, K.S., Bayard, F., and Arnal, J.F. The AF-1 activation-function of ER{alpha} may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc. Natl. Acad. Sci. U.S.A. 99, 2205–2210 (2002).[Abstract/Free Full Text]
  23. Dupont, S., Krust, A., Gansmuller, A., Dierich, A., Chambon, P., and Mark, M. Effect of single and compound knockouts of estrogen receptors {alpha} (ER{alpha}) and ß (ERß) on mouse reproductive phenotypes. Development 127, 4277–4291 (2000).[Abstract]
  24. Pare, G., Krust, A., Karas, R.H., Dupont, S., Aronovitz, M., Chambon, P., and Mendelsohn, M.E. Estrogen receptor-{alpha} mediates the protective effects of estrogen against vascular injury. Circ. Res. 90, 1087–1092 (2002).[Abstract/Free Full Text]
  25. Zhai, P., Eurell, T.E., Cooke, P.S., Lubahn, D.B., and Gross, D.R. Myocardial ischemia-reperfusion injury in estrogen receptor-{alpha} knockout and wild-type mice. Am. J. Physiol. Heart Circ. Physiol. 278, H1640–H647 (2000).[Abstract/Free Full Text]
  26. Pietras, R.J. and Szego, C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265, 69–72 (1977).[CrossRef][Medline]
  27. Pettersson, K. and Gustafsson, J.A. Role of estrogen receptor ß in estrogen action. Annu. Rev. Physiol. 63, 165–192 (2001).[CrossRef][Medline]
  28. Zhu, Y., Bian, Z., Lu, P. et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor ß. Science 295, 505–508 (2002).[Abstract/Free Full Text]
  29. Collins, P. and Webb, C. Estrogen hits the surface. Nat. Med. 5, 1130–1131 (1999).[CrossRef][Medline]
  30. Moggs, J.G. and Orphanides, G. Estrogen receptors: Orchestrators of pleiotropic cellular responses. EMBO Rep. 2, 775–781 (2001).[CrossRef][Medline]
  31. Honda, K., Sawada, H., Kihara, T., Urushitani, M., Nakamizo, T., Akaike, A., and Shimohama, S. Phosphatidylinositol 3'-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J. Neurosci. Res. 60, 321–327 (2000).[CrossRef][Medline]
  32. Simoncini, T., Hafezi–Moghadam, A., Brazil, D.P., Ley, K., Chin, W.W., and Liao, J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3'-OH kinase. Nature 407, 538–541 (2000).[CrossRef][Medline]
  33. Hisamoto, K., Ohmichi, M., Kurachi, H., Hayakawa, J., Kanda, Y., Nishio, Y., Adachi, K., Tasaka, K., Miyoshi, E., Fujiwara, N., Taniguchi, N., and Murata, Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 276, 3459–3467 (2001).[Abstract/Free Full Text]
  34. Denninger, J.W. and Marletta, M.A. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim. Biophys. Acta 1411, 334–350 (1999).[Medline]
  35. Chen, Z., Yuhanna, I.S., Galcheva-Gargova, Z., Karas, R.H., Mendelsohn, M.E., and Shaul, P.W. Estrogen receptor {alpha} mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 103, 401–406 (1999).[Medline]
  36. Hafezi-Moghadam, A., Simoncini, T., Yang, E., Limbourg, F.P., Plumier, J.C., Rebsamen, M.C., Hsieh, C.M., Chui, D.S., Thomas, K.L., Prorock, A.J., Laubach, V.E., Moskowitz, M.A., French, B.A., Ley, K., and Liao, J.K. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8, 473–479 (2002).[CrossRef][Medline]
  37. Fontana, J., Fulton, D., Chen, Y., Fairchild, T.A., McCabe, T.J., Fujita, N., Tsuruo, T., and Sessa, W.C. Domain mapping studies reveal that the M domain of HSP90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. 90, 866–873 (2002).[Abstract/Free Full Text]
  38. Nuedling, S., Kahlert, S., Loebbert, K., Meyer, R., Vetter, H., and Grohe, C. Differential effects of 17ß-estradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes. FEBS Lett. 454, 271–276 (1999).[CrossRef][Medline]
  39. Mital, S., Barbone, A., Addonizio, L.J., Quaegebeur, J.M., Mosca, R.J., Oz, M.C., and Hintze, T.H. Endogenous endothelium-derived nitric oxide inhibits myocardial caspase activity: Implications for treatment of end-stage heart failure. J. Heart Lung Transplant. 21, 576–585 (2002).[CrossRef][Medline]
  40. Di Domenico, M., Castoria, G., Bilancio, A., Migliaccio, A., and Auricchio, F. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res. 56, 4516–4521 (1996).[Abstract/Free Full Text]
  41. Castoria, G., Barone, M.V., Di Domenico, M., Bilancio, A., Ametrano, D., Migliaccio, A., and Auricchio, F. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J. 18, 2500–2510 (1999).[CrossRef][Medline]
  42. Endoh, H., Sasaki, H., Maruyama, K., Takeyama, K., Waga, I., Shimizu, T., Kato, S., and Kawashima, H. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem. Biophys. Res. Commun. 235, 99–102 (1997).[CrossRef][Medline]
  43. Jessop, H.L., Sjoberg, M., Cheng, M.Z., Zaman, G., Wheeler-Jones, C.P., and Lanyon, L.E. Mechanical strain and estrogen activate estrogen receptor {alpha} in bone cells. J. Bone Miner. Res. 16, 1045–1055 (2001).[CrossRef][Medline]
  44. Hwang, K.C., Lee, K.H., and Jang, Y. Inhibition of MEK1,2/ERK mitogenic pathway by estrogen with antiproliferative properties in rat aortic smooth muscle cells. J. Steroid Biochem. Mol. Biol. 80, 85–90 (2002).[CrossRef][Medline]
  45. Flores-Delgado, G., Bringas, P., Buckley, S., Anderson, K.D., and Warburton, D. Nongenomic estrogen action in human lung myofibroblasts. Biochem. Biophys. Res. Commun. 283, 661–667 (2001).[CrossRef][Medline]
  46. Scheuer, J., Malhotra, A., Schaible, T.F., and Capasso, J. Effects of gonadectomy and hormonal replacement on rat hearts. Circ. Res. 61, 12–19 (1987).[Abstract/Free Full Text]
  47. van Eickels, M., Grohe, C., Cleutjens, J.P., Janssen, B.J., Wellens, H.J., and Doevendans, P.A. 17ß-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104, 1419–1423 (2001).[Abstract/Free Full Text]
  48. Sugden, P.H. and Clerk, A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83, 345–352 (1998).[Free Full Text]
  49. Clerk, A., Michael, A., and Sugden, P.H. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: A role in cardiac myocyte hypertrophy? J Cell Biol 142, 523–535 (1998).[Abstract/Free Full Text]
  50. Razandi, M., Pedram, A., and Levin, E.R. Estrogen signals to the preservation of endothelial cell form and function. J. Biol. Chem. 275, 38540–38546 (2000).[Abstract/Free Full Text]
  51. Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R., and Grohe, C. Estrogen receptor {alpha} rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 275, 18447–18453 (2000).[Abstract/Free Full Text]
  52. Song, R.X., McPherson, R.A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., and Santen, R.J. Linkage of rapid estrogen action to MAPK activation by ER{alpha}–Shc association and Shc pathway activation. Mol. Endocrinol. 16, 116–127 (2002).[Abstract/Free Full Text]
  53. Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., and Auricchio, F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15, 1292–1300 (1996).[Medline]
  54. Migliaccio, A., Castoria, G., Di Domenico, M., de Falco, A., Bilancio, A., Lombardi, M., Barone, M.V., Ametrano, D., Zannini, M.S., Abbondanza, C., and Auricchio, F. Steroid-induced androgen receptor-oestradiol receptor ß-Src complex triggers prostate cancer cell proliferation. EMBO J. 19, 5406–5417 (2000).[CrossRef][Medline]
  55. Castoria, G., Migliaccio, A., Bilancio, A., Di Domenico, M., de Falco, A., Lombardi, M., Fiorentino, R., Varricchio, L., Barone, M.V., and Auricchio, F. PI3'-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20, 6050–6059 (2001).[CrossRef][Medline]
  56. Wong, B.R., Besser, D., Kim, N., Arron, J.R., Vologodskaia, M., Hanafusa, H., and Choi, Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041–1049 (1999).[CrossRef][Medline]
  57. Kubota, Y., Tanaka, T., Kitanaka, A., Ohnishi, H., Okutani, Y., Waki, M., Ishida, T., and Kamano, H. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3'-kinase. EMBO J. 20, 5666–5677 (2001).[CrossRef][Medline]
  58. Watters, J.J., Chun, T.Y., Kim, Y.N., Bertics, P.J., and Gorski, J. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol. Endocrinol. 14, 1872–1881 (2000).[Abstract/Free Full Text]
  59. de Jager, T., Pelzer, T., Muller-Botz, S., Imam, A., Muck, J., and Neyses, L. Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements. J. Biol. Chem. 276, 27873–27880 (2001).[Abstract/Free Full Text]
  60. Kato, S., Masuhiro, Y., Watanabe, M., Kobayashi, Y., Takeyama, K.I., Endoh, H., and Yanagisawa, J. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5, 593–601 (2000).[Abstract]
  61. Bunone, G., Briand, P.A., Miksicek, R.J., and Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15, 2174–2183 (1996).[Medline]
  62. Kato, S., Endoh, H., Masuhiro, Y. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491–1494 (1995).[Abstract/Free Full Text]
  63. Endoh, H., Maruyama, K., Masuhiro, Y. et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor {alpha}. Mol. Cell. Biol. 19, 5363–5372 (1999).[Abstract/Free Full Text]
  64. Aronica, S.M. and Katzenellenbogen, B.S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 7, 743–752 (1993).[Abstract/Free Full Text]
  65. Ignar-Trowbridge, D.M., Teng, C.T., Ross, K.A., Parker, M.G., Korach, K.S., and McLachlan, J.A. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol. Endocrinol. 7, 992–998 (1993).[Abstract/Free Full Text]
  66. Ignar-Trowbridge, D.M., Pimentel, M., Parker, M.G., McLachlan, J.A., and Korach, K.S. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137, 1735–1744 (1996).[Abstract]
  67. Rowan, B.G., Weigel, N.L., and O’Malley, B.W. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 275, 4475–4483 (2000).[Abstract/Free Full Text]
  68. Feng, W., Webb, P., Nguyen, P., Liu, X., Li, J., Karin, M., and Kushner, P.J. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine118-independent pathway. Mol. Endocrinol. 15, 32–45 (2001).[Abstract/Free Full Text]
  69. Pappas, T.C., Gametchu, B., and Watson, C.S. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 9, 404–410 (1995).[Abstract/Free Full Text]
  70. Ropero, A.B., Soria, B., and Nadal, A. A nonclassical estrogen membrane receptor triggers rapid differential actions in the endocrine pancreas. Mol. Endocrinol. 16, 497–505 (2002).[Abstract/Free Full Text]
  71. Razandi, M., Pedram, A., Greene, G.L., and Levin, E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ER{alpha} and ERß expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13, 307–319 (1999).[Abstract/Free Full Text]
  72. Kelly, M.J. and Levin, E.R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab. 12, 152–156 (2001).[CrossRef][Medline]
  73. Kuroki, Y., Fukushima, K., Kanda, Y., Mizuno, K., and Watanabe, Y. Putative membrane-bound estrogen receptors possibly stimulate mitogen-activated protein kinase in the rat hippocampus. Eur. J. Pharmacol. 400, 205–209 (2000).[CrossRef][Medline]
  74. Morey, A.K., Razandi, M., Pedram, A., Hu, R.M., Prins, B.A., and Levin, E.R. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem. J. 330, 1097–1105 (1998).
  75. Lu, Q., Ebling, H., Mittler, J., Baur, W.E., and Karas, R.H. MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor {alpha}. FEBS Lett. 516, 1–8 (2002).[CrossRef][Medline]
  76. Chambliss, K.L. and Shaul, P.W. Rapid activation of endothelial NO synthase by estrogen: Evidence for a steroid receptor fast-action complex (SRFC) in caveolae. Steroids 67, 413–419 (2002).[CrossRef][Medline]
  77. Kim, H.P., Lee, J.Y., Jeong, J.K., Bae, S.W., Lee, H.K., and Jo, I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor {alpha} localized in caveolae. Biochem. Biophys. Res. Commun. 263, 257–262 (1999).[CrossRef][Medline]
  78. Chambliss, K.L., Yuhanna, I.S., Mineo, C., Liu, P., German, Z., Sherman, T.S., Mendelsohn, M.E., Anderson, R.G., and Shaul, P.W. Estrogen receptor {alpha} and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ. Res. 87, E44–E52 (2000).
  79. Feron, O., Saldana, F., Michel, J.B., and Michel, T. The endothelial nitric-oxide-synthase–caveolin regulatory cycle. J. Biol. Chem. 273, 3125–3128 (1998).[Abstract/Free Full Text]
  80. Gratton, J.P., Fontana, J., O’Connor, D.S., Garcia-Cardena, G., McCabe, T.J., and Sessa, W.C. Reconstitution of an endothelial nitric–oxide synthase (eNOS), HSP90, and caveolin-1 complex in vitro. Evidence that HSP90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J. Biol. Chem. 275, 22268–22272 (2000).[Abstract/Free Full Text]
  81. Wyckoff, M.H., Chambliss, K.L., Mineo, C., Yuhanna, I.S., Mendelsohn, M.E., Mumby, S.M., and Shaul, P.W. Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through G{alpha}i. J. Biol. Chem. 276, 27071–27076 (2001).[Abstract/Free Full Text]
  82. Benten, W.P., Stephan, C., Lieberherr, M., and Wunderlich, F. Estradiol signaling via sequestrable surface receptors. Endocrinology 142, 1669–1677 (2001).[Abstract/Free Full Text]
  83. Guo, Z., Krucken, J., Benten, W.P., and Wunderlich, F. Estradiol–induced nongenomic calcium signaling regulates genotropic signaling in macrophages. J. Biol. Chem. 277, 7044–7050 (2002).[Abstract/Free Full Text]
  84. Moss, R.L. and Gu, Q. Estrogen: Mechanisms for a rapid action in CA1 hippocampal neurons. Steroids 64, 14–21 (1999).[CrossRef][Medline]
  85. Nethrapalli, I.S., Singh, M., Guan, X., Guo, Q., Lubahn, D.B., Korach, K.S., and Toran-Allerand, C.D. Estradiol (E2) elicits SRC phosphorylation in the mouse neocortex: The initial event in E2 activation of the MAPK cascade? Endocrinology 142, 5145–5148 (2001).[Abstract/Free Full Text]
  86. Singh, M., Setalo, Jr., G., Guan, X., Frail, D.E., and Toran-Allerand, C.D. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-{alpha} knock-out mice. J. Neurosci. 20, 1694–1700 (2000).[Abstract/Free Full Text]
  87. Osborne, C.K., Zhao, H., and Fuqua, S.A. Selective estrogen receptor modulators: Structure, function, and clinical use. J. Clin. Oncol. 18, 3172–3186 (2000).[Abstract/Free Full Text]
  88. Burger, H.G. Selective oestrogen receptor modulators. Horm. Res. 53 Suppl 3:25–29 (2000).
  89. Williams, J.K., Wagner, J.D., Li, Z., Golden, D.L., and Adams, M.R. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler. Thromb. Vasc. Biol. 17, 403–408 (1997).[Abstract/Free Full Text]
  90. Dardes, R.C., Schafer, J.M., Pearce, S.T., Osipo, C., Chen, B., and Jordan, V.C. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol. Oncol. 85, 498–506 (2002).[CrossRef][Medline]
  91. Walsh, B.W. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors. Ann. N.Y. Acad. Sci. 949, 163–167 (2001).[Medline]
  92. Hisamoto, K., Ohmichi, M., Kanda, Y., et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J. Biol. Chem. 276, 47642–47649 (2001).[Abstract/Free Full Text]
  93. Simoncini, T., Genazzani, A.R., and Liao, J.K. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105, 1368–1373 (2002).[Abstract/Free Full Text]
  94. Figtree, G.A., Lu, Y., Webb, C.M., and Collins, P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric-oxide-dependent mechanism. Circulation 100,1095–1101 (1999).[Abstract/Free Full Text]
  95. Wassmann, S., Laufs, U., Stamenkovic, D., Linz, W., Stasch, J.P., Ahlbory, K., Rosen, R., Bohm, M., and Nickenig, G. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105, 2083–2091 (2002).[Abstract/Free Full Text]
  96. Martel, C., Provencher, L., Li, X., St. Pierre, A., Leblanc, G., Gauthier, S., Merand, Y., and Labrie, F. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol. 64, 199–205 (1998).[CrossRef][Medline]
  97. Labrie, F., Labrie, C., Belanger, A., Simard, J., Giguere, V., Tremblay, A., and Tremblay, G. EM–652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol. 79, 213–225 (2001).[CrossRef][Medline]
  98. Simoncini, T., Varone, G., Fornari, L., Mannella, P., Luisi, M., Labrie, F., and Genazzani, A.R. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 143, 2052–2061 (2002).[Abstract/Free Full Text]
  99. Katzenellenbogen, B.S., Choi, I., Delage-Mourroux, R., Ediger, T.R., Martini, P.G., Montano, M., Sun, J., Weis, K., and Katzenellenbogen, J.A. Molecular mechanisms of estrogen action: Selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. 74, 279–285 (2000).[CrossRef][Medline]
  100. McDonnell, D.P., Chang, C.Y., and Norris, J.D. Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann. N.Y. Acad. Sci. 949, 16–35 (2001).[Medline]
  101. Lee, E.J., Jakacka, M., Duan, W.R., Chien, P.Y., Martinson, F., Gehm, B.D., and Jameson, J.L. Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice. Mol. Med. 7, 773–782 (2001).[Medline]
  102. Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn, T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson. J.A., and Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997).[CrossRef][Medline]
  103. Montano, M.M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P., and Katzenellenbogen. B.S. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc. Natl. Acad. Sci. U.S.A. 96, 6947–6952 (1999).[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
G. C. Douglas, C. A. VandeVoort, P. Kumar, T.-C. Chang, and T. G. Golos
Trophoblast Stem Cells: Models for Investigating Trophectoderm Differentiation and Placental Development
Endocr. Rev., May 1, 2009; 30(3): 228 - 240.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Hu, R. L. Gustofson, H. Feng, P. Ki Leung, N. Mores, L. Z. Krsmanovic, and K. J. Catt
Converse Regulatory Functions of Estrogen Receptor-{alpha} and -{beta} Subtypes Expressed in Hypothalamic Gonadotropin-Releasing Hormone Neurons
Mol. Endocrinol., October 1, 2008; 22(10): 2250 - 2259.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
R. K. Naz and R. Sellamuthu
Receptors in Spermatozoa: Are They Real?
J Androl, September 1, 2006; 27(5): 627 - 636.
[Full Text] [PDF]

Home page
 BioinformaticsHome page
H. Li and M. Zhan
Systematic intervention of transcription for identifying network response to disease and cellular phenotypes
Bioinformatics, January 1, 2006; 22(1): 96 - 102.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
Y. Merot, F. Ferriere, E. Debroas, G. Flouriot, D. Duval, and C. Saligaut
Estrogen receptor alpha mediates neuronal differentiation and neuroprotection in PC12 cells: critical role of the A/B domain of the receptor
J. Mol. Endocrinol., October 1, 2005; 35(2): 257 - 267.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, K. J.
Right arrow Articles by Liao, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, K. J.
Right arrow Articles by Liao, J. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.